ESR1 and prostate carcinoma: In hormone-dependent cancers, including breast and prostate cancers, SAFB2 expression is downregulated and delays tumor progression by inhibiting the transcriptional activities of androgen receptors (AR) and estrogen receptors α (ERα) (Zhen et al., 2023).